(Q36916630)

17 August 2017

1 reference

title

The emerging role of pharmacogenomics in biologics (English)

1 reference

17 August 2017

1 reference

E Lacaná

1

1 reference

17 August 2017

S Amur

2

1 reference

17 August 2017

P Mummanneni

3

1 reference

17 August 2017

H Zhao

4

1 reference

17 August 2017

F W Frueh

5

1 reference

17 August 2017

language of work or name

English

0 references

publication date

22 August 2007

1 reference

Clinical Pharmacology & Therapeutics

17 August 2017

1 reference

17 August 2017

82

1 reference

17 August 2017

4

1 reference

17 August 2017

466-471

1 reference

Trastuzumab in the treatment of metastatic breast cancer : anticancer therapy versus cardiotoxicity

17 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100334

Overcoming obstacles to monoclonal antibody product development and approval

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100334

7 January 2021

Development and regulation of monoclonal antibody products: challenges and opportunities

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100334

7 January 2021

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100334

7 January 2021

Infectious complications of biologic treatments of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100334

7 January 2021

Safety evaluation of biotechnology products

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100334

7 January 2021

Nonclinical safety evaluation of biotechnologically derived pharmaceuticals

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100334

7 January 2021

Early development of therapeutic biologics--pharmacokinetics.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100334

7 January 2021

Pharmacokinetic aspects of biotechnology products

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100334

7 January 2021

Immunogenicity of therapeutic proteins: clinical implications and future prospects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100334

7 January 2021

Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100334

7 January 2021

Characteristic sequence changes of hepatitis C virus genotype 2b associated with sustained biochemical response to IFN therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100334

7 January 2021

Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100334

7 January 2021

Hemolysis and methemoglobinemia secondary to rasburicase administration

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100334

7 January 2021

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100334

7 January 2021

Dysregulation of cellular signaling by HER2 in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100334

7 January 2021

Biologic and therapeutic role of HER2 in cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100334

7 January 2021

Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100334

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100334

7 January 2021

Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100334

7 January 2021

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100334

7 January 2021

Pharmacogenomics of tumor necrosis factor antagonists in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100334

7 January 2021

Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100334

7 January 2021

Tumour necrosis factor-alpha (TNF-alpha) levels and influence of -308 TNF-alpha promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100334

7 January 2021

Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100334

7 January 2021

Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100334

7 January 2021

Pharmacogenomic analysis of interferon receptor polymorphisms in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100334

7 January 2021

Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100334

7 January 2021

Interferon-beta treatment alters peripheral blood monocytes chemokine production in MS patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100334

7 January 2021

Identifiers

DOI

10.1038/SJ.CLPT.6100334

1 reference

17 August 2017

1 reference